Claims for Patent: 6,200,992

Summary for Patent: 6,200,992

Title:	Pharmaceutical composition for inhibiting the growth of cancers
Abstract:	A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a 1H-1,2,4-triazole derivative along with a safe and effective amount of a chemotherapeutic agent. Potentiators can be used to enhance the effectiveness of the drugs. The triazoles and potentiators compounds can also be used to treat viral infections.
Inventor(s):	Camden; James Berger (West Chester, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	08/674,182
Patent Claims:	1. A pharmaceutical composition in the form of a unit dosage composition for treating cancer susceptible to treatment in animals or humans comprising: (1) a pharmaceutically acceptable carrier; (2) a safe and enhanced amount of a 1H-1,2,4-triazole of the formula: ##STR3## wherein Z is an alkylene selected from the group consisting of CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH(CH.sub.3)--CH(CH.sub.3)-- and --CH.sub.2 --CH(alkyl) wherein said alkyl has from 1 to about 10 carbon atoms; and Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl, naphthyl and fluorenyl; (2) a safe and effective amount of chemotherapeutic agent; and (4) a safe and effective amount of potentiator wherein the amount of said potentiator enhances the effect of 1H-1,2,4-triazole in the treatment of cancer. 2. A composition according to claim 1 wherein said 1H-1,2,4-triazole is selected from the group consisting of: 1-[2-(2,4-dichlorophenyl)-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole; 1-[2-(2,4-dichlorophenyl)-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-ethyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazol e, 1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-pentyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, and acid addition salts thereof. 3. A pharmaceutical composition for treating cancer susceptible to treatment comprising: (1) a pharmaceutically acceptable carrier, (2) a safe and effective amount of a chemotherapeutic agent, (3) a safe and enhanced amount of a triazole of the formula: ##STR4## wherein Z is an alkylene selected from the group consisting of CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH(CH.sub.3)--CH(CH.sub.3)-- and --CH.sub.2 --CH(alkyl) wherein said alkyl has from 1 to about 10 carbon atoms; and Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl, naphthyl and fluorenyl and (4) a safe and effective amount of a potentiator wherein the amount of said potentiator enhances the effect of 1H-1,2,4-triazole in the treatment of cancer. 4. A pharmaceutical composition according to claim 3 comprising a pharmaceutically acceptable carrier and a safe and enhanced amount of a 1H-1,2,4-triazole selected from the group consisting of: 1-[2-(2,4-dichlorophenyl)-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole; 1-[2-(2,4-dichlorophenyl)-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-ethyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazol e, 1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-pentyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, and acid addition salts thereof. 5. A pharmaceutical composition according to claim 4 for inhibiting the growth of a tumor and wherein the chemotherapeutic agent is cisplatin. 6. A pharmaceutical composition according to claim 4 wherein said acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof. 7. A method of treating cancer in warm blooded mammals susceptible to treatment comprising administering a safe and effective amount of a chemotherapeutic agent, a safe and enhanced amount of a 1H-1,2,4-tiiazole derivative of the formula: ##STR5## wherein Z is an alkylene selected from the group consisting of CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --CH(CH.sub.3)--CH(CH.sub.3)-- and --CH.sub.2 --CH(alkyl) wherein said alkyl has from 1 to about 10 carbon atoms; and Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl, naphthyl and fluorenyly; and a safe and effective amount of potentiator wherein the amount of said potentiator enhances the effect of 1H-1,2,4-triazole in the treatment of cancer. 8. A method according to claim 7 wherein from about 2 mg/kg body weight to about 400 mg/kg of said 1H-1,2,4-triazole is administered and from 0.5 mg/kg body weight to about 40 mg/kg body weight of said chemotherapeutic agent is administered. 9. A method according to claim 8 wherein said 1H-1,2,4-triazole is administered orally or enterically, intravenously, peritoneally, parenterally or by injection. 10. A method according to claim 7 wherein said 1H-1,2,4-triazole is administered in a solid form, liquid form or as a liposome. 11. A method according to claim 10 wherein said 1H-1,2,4-triazole is selected from the group consisting of: 1-[2-(2,4-dichlorophenyl)-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole; 1-[2-(2,4-dichlorophenyl)-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-ethyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazol e, 1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, 1-[2-(2,4-dichlorophenyl)-4-pentyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazo le, and acid addition salts thereof. 12. A method according to claim 11 wherein said acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof. 13. A method according to claim 11 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive Agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, asparaginase and hydroxyurea. 14. A method of treating cancer according to claim 7 wherein said cancer is colon cancer. 15. A method of treating cancer according to claim 7 wherein said cancer is lung cancer. 16. A method of treating cancer according to claim 7 wherein said cancer is melanoma. 17. A method of treating cancer according to claim 7 wherein said cancer is ovarian cancer. 18. A method according to claim 7 wherein the potentiator is triprolidine.

Details for Patent 6,200,992

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2015-06-07